Bryce Point Capital LLC Purchases Shares of 3,522 United Therapeutics Co. (NASDAQ:UTHR)

Bryce Point Capital LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,522 shares of the biotechnology company’s stock, valued at approximately $1,243,000.

Other large investors also recently modified their holdings of the company. Wealthfront Advisers LLC grew its stake in United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the last quarter. Norges Bank bought a new stake in shares of United Therapeutics during the fourth quarter worth approximately $151,764,000. World Investment Advisors LLC acquired a new position in shares of United Therapeutics in the third quarter valued at approximately $139,206,000. Thrivent Financial for Lutherans increased its stake in shares of United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock worth $72,085,000 after purchasing an additional 189,967 shares during the period. Finally, AustralianSuper Pty Ltd lifted its holdings in United Therapeutics by 577.1% during the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock worth $66,962,000 after purchasing an additional 161,751 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Activity

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $940,373.07. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,500 shares of company stock worth $26,134,500. Corporate insiders own 11.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Price Performance

NASDAQ UTHR opened at $312.26 on Thursday. The business has a fifty day moving average price of $336.64 and a two-hundred day moving average price of $355.09. The stock has a market capitalization of $14.02 billion, a PE ratio of 13.71, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a fifty-two week low of $227.75 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period last year, the firm posted $4.36 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.